Clodronate Disodium Capsules

This product is a bone metabolism regulator that can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts.

Clodronate disodium

Capsules, the contents are white crystalline powder.

1. Hypercalcemia complicated by malignant tumors. 2. Bone pain caused by osteolytic cancer metastasis. 3. Can prevent or delay osteolytic bone metastasis of malignant tumors. 4. Various types of osteoporosis.

1. Paget's disease: 300 mg/day, intravenous drip for more than 3 hours, for 5 days, then oral administration. 2. Hypercalcemia: 300 mg/day, intravenous drip for 3-5 days or 1.5 g intravenous drip once, then oral administration after blood calcium returns to normal.

1. Dizziness and fatigue may occur in a few cases, but they usually disappear with continued treatment. 2. Adverse reactions such as increased serum lactate dehydrogenase and other liver enzyme levels, leukopenia, and abnormal renal function may sometimes occur.

1. It is contraindicated for those who are allergic to this product. 2. It is contraindicated for those with severe renal impairment or osteomalacia.

Not yet clear.

Sealed, store in a dry place.

0.4g

24 months

Harbin Pharmaceutical Group Sanjing Mingshui Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-30

• Address:

  Sanjing Pharmaceutical Industrial Park, Mingshui County, Suihua City, Heilongjiang Province

• Tax NO.:

  91231225726919956Y

• Registered Funds:

  40 million yuan

• Email:

  Log in to view